- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07621445
Genetic Risk Score of Type 1 Diabetes Mellitus for Progression to Insulin in Diabetic Patients Lack of Predictive Value: a Multicenter Nested Case-control Study
The goal of this observational study is to evaluate the predictive value of the genetic risk score for type 1 diabetes in the progression to insulin deficiency in diabetic patients. The main question it aims to answer is:
- To investigate the predictive efficacy of the genetic risk score for T1DM in determining whether diabetic patients will progress to insulin deficiency;
- To compare the differences in genetic characteristics between the insulin-deficient cohort and the non-insulin-deficient cohort.
This study is a nested case-control study, in which a case group and a control group are set up for the collection of observational indicators. Case group: Diabetic patients who "progressed to insulin deficiency" and those who "progressed to severe insulin deficiency". Control group: Patients who did not progress to insulin deficiency. The study period is 3 years.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Lieux d'étude
-
-
Hunan
-
Changsha, Hunan, Chine, 410011
- Recrutement
- Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University
-
Contact:
- Yang Xiao, MD/PhD
- Numéro de téléphone: 86-0731-85292154
- E-mail: xiaoyang29@csu.edu.cn
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
This study will enroll newly-diagnosed diabetic patients whose clinical subtype is unclear. Participants must be aged between 14 and 50 years, with a diabetes diagnosis within the past year, confirmed by standard American Diabetes Association (ADA) criteria. A key pathophysiological criterion is a peak C-peptide level < 200 pmol/L, suggesting impaired insulin secretion.
Key Exclusion Criteria: Patients will be excluded for conditions that could confound the etiology of diabetes or pose additional risks, including:
Specific diabetes subtypes (e.g., gestational diabetes, monogenic diabetes, pancreatic diseases).
Comorbidities such as malignant tumors or severe organ dysfunction. Acute metabolic derangements (e.g., ketoacidosis). Conditions limiting life expectancy or ability to participate (e.g., expected survival < 3 years, psychiatric disorders).
Current pregnancy or lactation.
La description
Inclusion Criteria:
- Gender is not restricted.
- Age ranges from 14 to 50 years old.
Diagnosis of diabetes within < 1 year:
- If there are diabetes symptoms and meet any of the following criteria:① Plasma glucose at any time ≥ 11.1 mmol/L (200 mg/dL), or② Fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL), or③ Plasma glucose 2 hours after OGTT/post - meal ≥ 11.1 mmol/L (200 mg/dL), or④ HbA1c ≥ 6.5%.
- If there are no diabetes symptoms, another test on a different day is required for diagnosis.
- Newly - diagnosed diabetes patients whose type diagnosis is considered unclear clinically.
Exclusion Criteria:
- Peak C-peptide < 200 pmol/L;
- Gestational diabetes, monogenic diabetes (neonatal diabetes, MODY), exocrine pancreatic diseases (cystic fibrosis), diabetes caused by drugs or chemicals;
- Those who have been under long-term treatment with hormones or immunosuppressants;
- Pregnant or lactating women;
- Those with concurrent malignant tumors or severe heart, liver, and kidney diseases;
- Those with an expected survival time of less than 3 years;
- Those with mental disorders or unable to cooperate with the investigation for other reasons;
- Acute phase of diabetic ketoacidosis;
- Stress conditions such as severe infection, fever, trauma, and major surgery;
- Patients lacking major clinical information;
- Those considered by the researcher as unfit to participate in this study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Patients with diabetes who 'progress to insulin deficiency and severe insulin deficiency'
Patients with diabetes who 'progress to insulin deficiency' and 'progress to severe insulin deficiency'
|
|
Patients who have not progressed to insulin deficiency
For each case, several controls (1:2) were randomly selected from patients in this cohort who had not progressed to insulin deficiency at the same follow - up time point.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
C-peptide
Délai: "baseline"、"third year"
|
The primary endpoint is the occurrence of progression to insulin deficiency.
Subjects who "progress to insulin deficiency" are defined as those whose C-peptide level drops to C-peptide < 250 pmol/L during the follow - up period;
|
"baseline"、"third year"
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Fasting and 2 - hour blood glucose
Délai: "baseline"、"third year"
|
"baseline"、"third year"
|
|
|
Glycosylated hemoglobin
Délai: "baseline"、"third year"
|
"baseline"、"third year"
|
|
|
Whether insulin treatment is needed
Délai: "baseline"、"third year"
|
Collect the medical history and current medication information of the subjects.
|
"baseline"、"third year"
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies du système endocrinien
- Processus pathologiques
- Attributs de la maladie
- Maladies métaboliques
- Maladies auto-immunes
- Maladies du système immunitaire
- Troubles du métabolisme du glucose
- Sensibilité aux maladies
- Prédisposition génétique à la maladie
- Conditions pathologiques, signes et symptômes
- Maladies nutritionnelles et métaboliques
- Score de risque génétique
- Diabète sucré
- Diabète sucré, type 1
Autres numéros d'identification d'étude
- 2025 T1DGRS LYF20250124
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .